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Abstract
The term ‘epigenetics’ refers to a series of meiotically/mitotically inheritable alterations in gene expression, related to environmental factors,
without disruption on DNA sequences of bases. Recently, the pathophysiology of autoimmune diseases (ADs) has been closely linked to epi-
genetic modifications. In fact, epigenetic mechanisms can modulate gene expression or repression of targeted cells and tissues involved in
autoimmune/inflammatory conditions acting as keys effectors in regulation of adaptive and innate responses. ADs, as systemic lupus erythe-
matosus (SLE), a rare disease that still lacks effective treatment, is characterised by epigenetic marks in affected cells. Taking into account that
epigenetic mechanisms have been proposed as a winning strategy in the search of new, more specific and personalised therapeutics agents,
pharmacology and pharmaco-epigenetic studies about epigenetic regulations of ADs may provide novel individualised therapies. Focusing on
possible implicated factors on development and predisposition of SLE, diet is feasibly one of the most important factors since it is linked directly
to epigenetic alterations and these epigenetic changesmay augment or diminish the risk of SLE. Nevertheless, several studies have suggested that
dietary therapy could be promising to SLE patients via prophylactic actions deprived of side effects of pharmacology, decreasing co-morbidities
and improving lifestyle of SLE sufferers. Herein, we review and discuss the cross-link between epigeneticmechanisms on SLE predisposition and
development, as well as the influence of dietary factors on regulation of epigenetic modifications that may eventually make a positive impact on
SLE patients.
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Introduction
Epigenetics has been defined as a series of reversible and inher-
itable alterations capable of regulating genetic expression and
stability. These mechanisms support cellular growth, develop-
ment and differentiation, but they do not disrupt DNA sequences
of bases(1). The epigenetic settings may be orchestrated by sev-
eral factors such as the aging process or environmental
influences such as smoke, climate, nutrition, viral infections,
chemical exposures, etc.(2). Three main epigenetic mechanisms
involved are DNA methylation, histone modifications and non-
coding RNA profiling (Fig. 1).
1. DNA methylation. DNA methylation is the most traditional
and well-known epigenetic event. It is involved in several
pathologies, considered as a basic process of cellular devel-
opment and growth. This procedure involves the transfer-
ence of a methyl group from S-adenosylmethionine (SAM)
to 5 0-carbon position of cytosine residues in cytosine-phos-
phate-guanosine (CpG) dinucleotides on DNA strand. The
CpG islands are located near promoter regions and transcrip-
tion start sites. For that reason, the methylated CpGs sites
result in inaccessible heterochromatin for transcription effec-
tors, inducing genic silencing. Contrarily, the non-methylated
sequences remain accessible, and transcription goes on(3,4).
DNA methylation is executed by DNA methyltransferase
(DNMT) enzymes. According to de novo or maintenance
states of methylation, it may be conducted by DNMT3 or
DNMT1, respectively.
2. Histone modifications. Histones are proteins that wrap DNA
to form nucleosome structures. The main post-translational
alterations of histones are acetylation/deacetylation, methyla-
tion/demethylation, phosphorylation and ubiquitination.
These modifications at terminal amino acid modulate the
accessibility to transcriptional factors and gene expression(5).
Some studies have postulated a relation between DNA
methylation and histone modifications that reorganises chro-
matin and blocks gene expression(6).
3. Noncoding RNAs (ncRNAs). Long noncoding (lnc) (>200
nucleotides) and short ncRNAs (miRNA) (<200 nucleotides)
modulate expression or repression at the transcriptional and
post-transcriptional level, regulating chromatin formation, his-
tone modifications and DNA methylation. miRNAs have been
extensively studied in autoimmune and chronic inflammation,
being postulated as biomarkers and therapeutic targets. In
addition, miRNAs bind to complementary target mRNAs and
suppress translation by degradation of this target(7).
Themaintenance of proper function andbalance between epi-
genetic processes is essential to normal development and action
of immune system. However, increasing evidence has shown that
epigenetic deregulated modifications, including DNA
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methylation, histonemodification andncRNAs, are involved in the
pathogenesis of several autoimmune diseases (AD). Besides, the
alterations of epigenome are implicated in the dysregulation of
signalling molecules and receptors of various autoimmune/
inflammatory conditions(6,8). Also, it has been reported that ADs
are related to genetic predisposition and environmental factors,
whose effects induce epigenetic modifications(9).
Consequently, epigenetic events could play a relevant role in
the aetiology and pathogenesis of ADs, even promising a poten-
tial future therapeutic intervention. In fact, it has been proposed
as a plausible strategy in the research of new therapeutic agents
that are more specific and personalised. Thus, pharmacologic
and pharmaco-epigenetic studies on reversible epigenetic regu-
lations of autoimmune pathologies to drug responses may pro-
vide novel individualised therapies(3,8,9).
ADs like systemic lupus erythematosus (SLE), rheumatoid arthri-
tis (RA), psoriasis ormultiple sclerosis, among others, are character-
ised by epigenetic marks in affected cells(3). Despite the fact that
total extension of epigenetic modifications in these pathologies
remains unclear, this characteristic could indicate a definitive
approach to patients who are exposed to chronic therapy whose
side effects can make day-to-day life difficult for patients(7).
Overall, nutrition is one of the most accessible external fac-
tors implicated in ADs, so its influence on the epigenetics profile
of ADs should be considered. Additionally, the knowledge of
micronutrient action in epigenetic patterns of ADs could indicate
a promising strategy to prevent them. Nevertheless, the studies
that investigate the effects of bioactive compounds in the context
of epigenetic alterations have been focused mainly on cancer.
Consequently, in the present review, we intend to summarise
up-to-date preclinical and clinical studies on epigenome altera-
tions of SLE and discuss the potential roles of epigenetic regula-
tion by dietary bioactive compounds.
Systemic lupus erythematosus (SLE)
SLE is an autoimmune multiorgan disease characterised by its
clinical and pathogenic complexity that can damage different
Fig. 1. Schematic epigenetic modifications: histone modifications, DNA methylation and ncRNAs. DNA is wrapped around histones to form nucleosomes. Histone
acetylation opens the chromatin, enabling transcription with activation of genes. Contrarily, deacetylation or methylation of histones condenses the chromatin, making
it inaccessible for transcription components. DNA methylation is operated by DNMTs that add methyl groups on CpG island in the promoter region of a gene. DNA
methylation blocks the binding of transcription factors and results in suppression of gene expression. In unmethylated DNA sequences, the transcription machinery
is capable to transcribe and gene is active. ncRNAs regulate gene expression or silencing at the transcriptional or post-transcriptional level.
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organs such as skin, kidneys, joints, lungs, coronary system and
liver, among others(10,11). Difficult diagnosis, alternated and
unpredictable exacerbation and remission periods during the
course of disease, in addition to the high number of complica-
tions, affect the patient’s quality of life.
This AD is characterised by loss of tolerance to self-antigens
and, thus, overactivation of B and T cells, increasing the produc-
tion of anti-nuclear autoantibodies, immune complex deposi-
tion, lymphoproliferation and expression of inflammatory
cytokines that may initiate and amplify inflammation, contribut-
ing to the clinical manifestations of SLE(12).
SLE is considered a rare disease, according to EC Regulation
on Orphan Medicinal Products. Demographically, the preva-
lence of the disease is approximately 20–150 cases per 100
000 individuals worldwide. Besides, approximately 90 % of
the patients are fertile women between 20 and 30 years old,
although it can appear at any age (13,14).
Even though aetiopathogenesis of SLE is not totally defined,
genome-wide association studies have revealed several roles to
genetic predisposition in lupus patients. However, the discord-
ance for SLE between monozygotic twins described by Deapen
et al., in 1992, suggested that other non-genetic factors possibly
regulate disease onset (15). Exposure to UV light, smoking, con-
sumption of some drugs or inadequate dietary habits could neg-
atively condition the epidemiology of SLE (10).
Recently, epigenetics has been postulated as an environmen-
tal driver that contributes to the aetiology of SLE. In 2010, Javierre
and colleagues revealed for the first time that monozygotic dis-
cordance on SLE features widespread alterations in DNA
methylation status of several genes. Individual analysis con-
firmed different profiles of methylation and expression in genes
related to SLE pathology (16). As a result, discordance between
twins allowed the identification of epigenetic targets and high-
lights their potential contribution to SLE.
The presence of X chromosomes is positively related to high
risk for SLE. Nevertheless, the implicated epigenetic features
remain unclear. Recently, Syrett and colleagues have established
that the sticking female predilection of this disease is caused by
the defective inactivation of X chromosome. Females normally
inactivate one X chromosome to balance X-linked genes with
the male sex (17). The inactivation process is started in early
development, where each female cell randomly determines to
silence the paternal or maternal X chromosome, by allele-spe-
cific up-regulation of the long noncoding RNA (lncRNA) Xist
from the future inactive X. Xist RNA recruits heterochromatin
modifications (H3K27me3 and H2-ubiquitin) across the X
chromosome, inducing a transcriptional silencing. They
observed that Xist RNA disappeared from the X inactive chromo-
some, and X chromosome inactivation maintenance was altered
in the maturation of thymocytes and T-cell subsets from SLE
patients and mice. Consequently, SLE patients’ T cells exhibited
up-regulated X-linked genes(17). Accordingly, the hypomethyla-
tion of several genes encoded to X chromosome, such as TRL7 or
CD40L, which are implicated in the development of immune
response, have been described in lupus disease and pathophysi-
ology. In fact, CD40LG, a B-cell co-stimulatory molecule, is over-
expressed in lupus lymphocytes and contributes to an
exacerbated production of autoantibodies (3,4,6,18).
Variations of epigenome on SLE
DNA methylation, histone modifications and miRNA expression
have been thoroughly defined in in vitro and in vivo experimen-
tal studies, using peripheral bloodmononuclear cells (PBMCs) of
SLE patients or animal models, that have shown that variation of
the epigenome may lead to the onset of SLE.
DNA methylation in SLE
Recent studies have confirmed that DNA hypomethylation is a
dominant factor in SLE (Table 1). In consequence, some deme-
thylating agents are known to promote drug-induced experi-
mental lupus (19).
Lupus-like autoimmunity and severity is associated with
CD70 (so TNFSF7 encoded) and C11a (so TNFSF5 encoded)
overexpression in CD4þ T cells. This fact has been related to
DNA hypomethylation on their respective promoters. CD70 is
expressed in activated T cells and increases IgG synthesis, col-
laborating in B-cell co-stimulatory functions (20). On the other
hand, CD11a (ITGAL encoded) is an integrin implicated in co-
stimulation and cellular adhesion and also related to leucocyte
function-associated antigen (LFA) 1. Increased LFA1 in T cells
from lupus patients involves an autoreactive phenotype of lupus
(43). Zhao et al. (2010a) established that the overexpression of
CD70 and CD11a in SLE CD4þ T cells was the result of the
DNMT1 recruitment at the CD70 and CD11a promoter region,
orchestrated by regulatory factor X (RFX) 1. RFX1 works like
an immune-suppressor and is usually decreased in SLE patients’
cells, so it seems to be involved in lupus pathogenesis (20).
Conclusively, regulation of RFX1 in lupus patients provides a
valuable insight into methylation-dependent gene expression
on CD70/CD11a axis, which promotes autoimmune response.
Furthermore, Luo et al. (2010) compared CD70 expression levels
and methylation status of CD70 promoter region in CD4þ T cells
from patients with subacute cutaneous lupus erythematosus
(SCLE) and healthy controls. The results showed a CD70 sur-
face-overexpressed and CD70-demethylated promoter region
in CD4þ T cells from SCLE patients compared with cells from
healthy subjects, concluding that demethylation of regulatory
elements could contribute to the increase of CD70 expression
in patients with SCLE (21).
Surprisingly, an interesting in vitro study showed reduced
expression of RFX1 in CD4þ T cells from patients with SLE, lead-
ing to interleukin (IL) 17A overexpression through decreased
DNA methylation. The results revealed that RFX1 deficiency
increased the differentiation of naïve CD4þ T cells into Th17
cells. Furthermore, the same researchers demonstrated that con-
ditional deletion of RFX1 in mice exacerbated experimental pris-
tane-induced lupus-like syndrome and increased Th17 cell
induction. These data revealed that RFX1 functions downstream
of the signal transducer and activator of transcription (STAT) 3
and phosphorylated-STAT3, inhibiting their expression, high-
lighting a non-canonical pathway that regulated differentiation
of Th17 cells (25).
Additionally, previous studies have investigated inhibition of
DNMT1 activity, confirming the DNA hypomethylation profile is
characteristic in lupus cells. Deng and co-workers have shown
that T cells from patients with active lupus had diminished
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Table 1. DNA methylation altered patterns in SLE
Experimental system Target Action Reference
SLE CD4þ T cells Recruitment of DNMT1 CD70 and CD11a overexpression (20)
Hypomethylation of CD70 and CD11a promoter
CD4þ T cells from SCLE patients Hypomethylation of CD70 promoter CD70 overexpression (21)
T cells from SLE patients DNA hypomethylated at IL4 and IL6 promoter regions Elevated IL4 and IL6 mRNA levels (22)
Association with severity of SLE
CD4þ T lymphocytes from SLE patients and
human Jurkan T cells
Hypomethylated IL17F promoter region Regulation of IL17F production (23)
T cells from SLE and RA patients and healthy
controls
DNMT3 recruitment IL2/IL17A imbalanced expression levels (24)
Hypomethylation at IL17A promoter
CD4þ T cells from SLE patients DNA hypomethylation Reduction of RFX1 expression (25)
IL17A overexpression
PBMC from SLE Low DNA methylation level of IFI44L promoter Increased IFI44L expression (26)
Different IFI44L levels between SLE patients with or without renal abnormalities
SLE CD4þ T cells Increased hydroxymethylation in promoter regions of
SOCS1, NRF2F6, IL15RA
Up-regulation of immune-related genes (SOCS1, NRF2F6, IL15RA) and signal-
ling pathways (Wnt, MAPKs, mTOR)
(27)
CD4þ CD28þ KIRþ CD11ahi T cells from female
SLE patients
DNA hypomethylation Induction of pro-inflammatory and transcriptional profiles in SLE (28)
CD28þ and CD28− T cells from SLE patients DNA hypomethylation Aberrant KIR overexpression (29)
IFN overproduction
Induction of macrophage activation
SLE T cells DNA hypomethylation in PP2Ac promoter region Increment of PP2Ac expression and SLE disease activity (30)
Decreased DNMT1 levels
T cells from active SLE and inactive SLE patients Down-regulation of DNMT and DNA hypomethylation Decrease of signalling Ras-MAPK pathway (31)
CD4þ T cells from SLE patients Global DNA hypomethylation Low levels of gadd45A and CD11a/CD70 mRNA (32)
SLE CD4þ T cells DNA hypomethylation of regulatory regions of CD11a
and CD70 genes
Increased high-mobility group box protein 1 (HMGB1) and CD11a and CD70
mRNA
(33)
CD4þ and CD8þ T cells from active SLE patients Hypomethylation of PRF1 promoter Perforin overexpression (34)
SLE women CD4þ T cells DNA demethylation of CD40LG and CD70 Overexpression of CD40LG mRNA and CD70 (18,35)
B-cell stimulation and IgG production
CD4þ T cells from SLE patients DNA hypomethylation at IL-10 and IL-13 enhancer and
promoter regions
Increased IL10 and IL13 mRNA and protein expression (36)
Induction of autoantibody production and tissue damage
SLE B cells Demethylation of CpG islands in the CD5-E1B pro-
moter
Down-regulation of membrane CD5 level (37)
Activation and expansion of autoreactive B cells
Blood from SLE women Hypomethylation of 16 CpG sites in 11 genes Association with antibody production in SLE (38)
PBMC from SLE with or no LN Aberrant DNA methylation in MX1, GPR84, E2F2 rel-
evant genes
Increased gene expression (MX1, GPR84, E2F2) (39)
Elevated levels of inflammatory cytokines
CD4þ T cells, CD19þ B cells and CD14þ mono-
cytes from SLE patients
Severe hypomethylation in related-IFN genes IFN-mediated hypersensitivity (40)
SLE CD4þ T cells Global DNA hypomethylation Modulation of autoimmune response (41)
Low levels of DNMT1 Aberrant IgG level





















niversidad de Sevilla, on 30 N
ov 2021 at 15:45:24, subject to the Cam
bridge Core term






DNMT mRNA levels decreasing the Ras–mitogen-activated pro-
tein kinase (Ras-MAPK) signalling. The inhibition of signalling
through the Ras-MAPK pathway with a soluble inhibitor of
MAPK ERK I (MEK1) decreased DNMT mRNA and their enzyme
activity, similarly to DNA hypomethylation in SLE T cells. These
results suggested that a decrease in Ras-MAPK pathway signal-
ling could be involved in down-regulation of DNMT activity in
association with DNA hypomethylation in patients with lupus
(31). In addition, transgenic mouse with impaired ERK pathway
signalling in T cells exhibited low expression of DNMT1 and
up-regulation of autoreactivity-related methylation-sensitive
genes (CD70, CD11a), increased anti-dsDNA antibodies levels
and glomerulonephritis (44–46).
Furthermore, recent studies have confirmed that a catalytic
subunit of protein phosphatase 2A (PP2Ac), overexpressed in
SLE T cells, is involved in the alteration of DNMT1 activity by
the impairment of T-cell phosphorylation of MEK/ERK signalling
pathways. Sunahori et al. investigated DNAmethylation patterns
in the PP2Ac promoter region in SLE T cells, compared with nor-
mal T cells. Specifically, in T cells from patients with active SLE,
the suppression of PP2Ac increased phosphorylation of signal-
ling pathway upstream of DNMT1 expression and activity and,
thus, suppressed CD70 and CD11a expression. They concluded
that PP2Ac may be a key target to control the methylation of sen-
sitive genes in SLE T through dephosphorylation of MEK/ERK
signalling pathway and activation of DNMT1 (30,47).
However, although there are many clinical studies that sup-
port the role of DNA methylation in the pathogenesis of lupus,
there are only a few in vivo studies of DNA methylation implica-
tion in the development of this autoimmune disorder. In 2007,
Sawalha et al. studied the existence of correlation between
age-dependent autoimmunity in MRL-lpr mice and the
decreased expression of DNMT1 and, consequently, T-cell
DNA hypomethylation. They found lower levels of DNMT1
steady state in 16-week-old MRL-lpr mice compared with 5-
week-old mice. Also, they described that 16-week-old mice pre-
sented hypomethylated CpG pairs compared with 5-week-old
MRL-lpr mice (48). As a consequence, they concluded that
reduced expression of DNMT1 and the corresponding T-cell
DNA hypomethylation were correlated directly with the devel-
opment of age-dependent autoimmunity in MRL/lpr mice.
Additionally, Hedrich et al. investigated CpG-DNA methyla-
tion patterns in conserved noncoding sequence regions and
proximal promoter region of human IL17F gene in resting and
activated naïve CD4þ T lymphocytes from healthy controls or
total T lymphocytes from SLE patients. They observed that SLE
T cells displayed lower degrees of CpG-DNA methylation as
compared with control T lymphocytes in response to T cells.
This fact suggested that IL17F production in human T lympho-
cytes could be regulated by CpG-DNA methylation (23). In this
sense, these researchers also studied epigenetic regulators to
diametric expression of IL2 and IL17A, whose tight balance is
essential for immune homeostasis. They demonstrated that
cAMP response element modulator (CREM) α contributed to epi-
genetic remodelling of the IL2 and IL17A genes during T-cell dif-
ferentiation. Furthermore, the epigenetic modulation of IL2
through DNMT3a recruitment resulted in trans-activation and
demethylation of IL17A promoter. This imbalance between
IL2 and IL17A expression levels is a hallmark characteristic of
autoimmune disorders, such as SLE (24).
Other targets analysed to show the potential role of DNA
methylation in the regulation of gene expression in SLE were
IL4 and IL6 transcripts. Mi et al. (2008) studied in T cells isolated
from SLE patients and healthy controls changes of DNAmethyla-
tion in IL4 and IL6 promoters. They demonstrated that levels of
IL4 and IL6 mRNA transcripts were significantly higher in SLE T
cells, as compared with controls. Therefore, hypomethylation of
both promoters occurred in T cells from SLE patients and was
associated with the severity of SLE (22).
IFI44L is considered a highly sensitive and specific diagnostic
marker for SLE. Zhao et al. (2016a) found that methylation level
of IFI44L promoter could distinguish patients with SLE from
healthy people and other ADs; thus, it could be considered a sen-
sitive and specific diagnostic marker for this pathology.
Furthermore, the DNA methylation level within the IFI44L pro-
moter was significantly lower in patients with SLE with renal
involvement than in SLE patients without renal abnormalities
(26). In this line, stimulatory and killer cell inhibitory immuno-
globulin-like receptor (KIR3) was overexpressed in T cells
unmethylated from SLE patients (CD28þ and CD28−), propor-
tionally to degree of disease, through promotion of killing of
macrophages and increase in interferon (IFN) γ level, suggesting
that antibodies to inhibitory KIR may be a treatment for this
disease (49).
Overall, the wide study of overexpression of different genes
such as CD11a and KIR from CD4þ and CD28þ T cells might
explain genetic risk and disease activity in lupus. In fact,
CD4þCD28þKIRþCD11ahi T cells are demethylated and charac-
terised by pro-inflammatory epigenetic and transcriptional pro-
files in SLE. Thus, it was suggested that removing these cells or
blocking their pro-inflammatory outlines could be considered a
novel approach to treatment of lupus (28).
On the other hand, Zhao and colleagues (2016) detected
increased 5-hydroxymethylxytosine (5-hmC) levels, a novel dis-
covered modified form of cytosine, in genomic DNA in CD4þ T
cells from SLE patients, compared with healthy controls. This
result was accompanied by up-regulated expression of ten-
eleven translocation (TET)-2 and TET-3, which can enzymati-
cally convert 5-methylcytosine (5-mc) into 5-hmC. Also, these
researchers found differences between DNA hydroxymethyla-
tion patterns from SLE patients and healthy controls, such as
Wnt, MAPKs or mTOR signalling pathways and selected
immune-related genes (SOCS1, NRF2F6 and IL15RA). Finally,
they concluded that hydroxymethylation is implicated in aber-
rant regulation of genes in pathogenesis of SLE; thus, 5-hmC
could provide a new tool for treating this disorder (27).
Conclusively, these recent advances have shown that altered
DNA methylation patterns have a plausible potential as bio-
markers for diagnosis and outcome assessment, as well as
objects for target and individualised interventions in SLE (50).
Histone modifications in SLE
Histones have octamer forms with two of each histone core
(H2A, H2B, H3 and H4), which wrap DNA around them. This
conformation enables the accessibility to transcriptional factors
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and gene expression to be controlled (6,51,52). Until now, themain
histonemodifications studied in SLE are acetylation andmethyla-
tion. Both processes are mediated by different enzymes with
opposite and reversible functions (53). In the acetylation process,
an acetyl group is transferred to lysine residue on N-terminal tail
by histone acetyltransferase (HAT) enzymes (6). This modifica-
tion promotes an accessible chromatin structure, increasing
the accessibility of DNA to transcription factors. For this reason,
H3 and H4 hyperacetylation is commonly associated with gene
activation. Contrarily, histone deacetylases (HDACs) catalyse the
reverse process, removing acetyl groups and contributing to
gene silencing through the condensation of nucleosomes and
compaction of chromatin structure (4,54,55). Related to histone
methylation, this can affect lysine and arginine residues (56).
Histone methyltransferases can add up to three methyl groups.
However, depending on methylation degree and residues
involved, gene regulation could be up-regulated or repressed
(4,11,53). For example, it has been described that hypermethyla-
tion of histone 4 lysine 4 trimethylation (H4K4me3) is associated
with gene transcription, while H3K4me3 presents a repressive
effect (43).
Interesting studies have established that histone modifica-
tions contribute to SLE pathogenesis (Table 2). In fact, some
of them have identified aberrant global methylation or acetyla-
tion of H3 and H4 in SLE patients compared with healthy con-
trols. Nevertheless, the involvement of this epigenetic process
in SLE remains unclear.
Monocytes are implicated in atherosclerosis and renal dis-
ease, contributing to mortality in SLE patients. Moreover, mono-
cyte dysfunction induces production and response to IFN. In
monocytes from lupus patients, global H4 acetylation of several
genes has been reported to be significantly altered (59,62,63).
However, more than 50 % of H4-hyperacetylated genes are
related to interferon regulatory factor (IRF) 1. IRF1 is a transcrip-
tion factor in antiviral and immune response with anti-tumour
effects. IRF1 can be induced by IFNs and tumour necrosis factor
(TNF)-α, suggesting that IFN contributes to SLE pathogenesis
(5,85). Sullivan et al. (2007) revealed up-regulated ratios of
H4ac in SLE monocytes at the TNF-α locus compared with
healthy controls. They concluded an increased transcription of
TNF- α, playing a key role in the inflammatory response that
is seen in lupus patients (57).
The raised possibility that decreased histone acetylation
might contribute to lupus pathogenesis by promoting silencing
of some genes has been amply studied. García et al. (2005)
described for the first time a global site-specific hypermethyla-
tion (except H3K4 methylation) and hypoacetylation in histone
H3 and H4 MRL-lpr/lpr mice in comparison with control MRL/
MPJ mice (83). In agreement, Hu et al. showed that SLE CD4þ
T cells had decreased overall acetylation of both H3 and H4,
and they correlated the negative relation between the degree
of H3 hypoacetylation with SLE disease activity (75).
In early stages of lupus nephritis (LN), Wardowska and col-
leagues observed a significant decrease in H3K4me3 and
H3K29me3 marks in dendritic cells that could reveal renal
involvement in SLE, serving as distinctive biomarkers in the diag-
nosis of lupus nephritis and monitoring of renal outcome in SLE
patients (53). In this line, H3K4me3 has been recognised as a
potential biomarker associated to SLE pathogenesis, and it could
be a promising target for epigenetic-based lupus therapies.
CREM α alters epigenetic conformation of cytokine gene by
way of histone acetylation in active SLE T cells. HDAC is
recruited to CRE sites in the IL2 promoter, and IL-2 expression
is repressed (86–88). Moreover, hyperacetylation of histone 3
lysine 18 (H3K18) and hypomethylated histone 3 lysine 27
(H3K27) at IL17A-IL17F promoters induce low levels of IL2
and IL17F, while IL17A is overexpressed (23,70,89). Hedrich
et al. (2017) agreed with these data and reported an increase
in H3K27me3 and poor H3K18ac levels at IL2 promoter that
silenced IL2 secretion (50).
Liu and colleagues studied in vitro TLR-2-stimulated CD4þ T
cells from SLE patients, and they observed an increment of trime-
thylation into histone 3 lysine 4 (H3K4me3), and H4 acetylation
together with trimethylated histone 3 lysine 9 (H3K9me3)
decreased in the IL17A-IL17F promoter region (73). These data
could confirm that histone modifications in SLE through TLR-2
stimulation promoted IL17A and IL17F expression, developing
immune reactivity. Likewise, Apostolidis et al. (2013) reported
that PP2Ac, a serine/threonine phosphatase highly expressed
in SLE cells, enhanced IL17 gene expression thought H3ac in
murine T cells, predisposing glomerulonephritis affection (84).
IL10 is the second cytokine with enhanced expression corre-
lated with disease activity and antibody production in lupus
patient’s serum and tissues. Hedrich and colleagues investigated
STAT3- and STAT5-mediated trans-activation and epigenetics
remodelling of IL10 gene related to HAT p300. They concluded
that the enhanced activation of STAT3 through transcriptional
cofactor p300 produces a competitive replacement of STAT5
in regulatory regions and, consequently, the promotion of
IL10 expression (74).
TNF-α-induced protein 3 (TNFAIP3) is a key SLE susceptibil-
ity gene implicated in the modulation of inflammatory responses
through nuclear factor-κB (NF-κB) pathway. Zhao et al. studied
TNFAIP3 expression in CD4þ T cells and the molecular mecha-
nism underlying TNFAIP3 regulation in the pathogenesis of SLE,
suggesting that the down-regulation of TNFAIP3 in CD4þ T cells
of SLEwas probably regulated by demethylation of H3K4, which
led to a reduced quantity of H3K4me3 in the promoter of the
TNFAIP3 gene. The dysregulation of TNFAIP3 in CD4þ T cells
could play a role in the pathogenesis of SLE by over-production
of inflammatory cytokines IFN-γ and IL17. Thus, they conclude
that TNFAIP3may provide a promising target for the treatment of
SLE in clinical practice (77).
As aforementioned, the expression and activity of the tran-
scription factor RFX1 were decreased in SLE CD4þ T cells.
Zhao and colleagues demonstrated that RFX1 affected DNA
methylation and histone acetylation in CD4þ T cells by recruiting
the co-repressors DNMT1 and HDAC1 to the CD11a and CD70
promoters, and thereby suppressed their expression. Reducing
RFX1 in CD4þ T cells was enough to induce lupus-like T- and
B-cell hyperactivity, whereas overexpressing RFX1 blocked T-
cell reactivity. These findings confirm a crucial role for RFX1
in regulating the epigenetic status of T cells, and reveal that auto-
immune responses in SLE are responsible in part to RFX1 down-
regulation. Moreover, these authors showed that reduced
expression of the transcription factor RFX1 in CD4þ T cells from
6 T. Montoya et al.
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Table 2. Histone alterations in SLE
Cell source Histone alterations Effect References
Human SLE Monocytes ↑ H3 and H4 acetylation at TNF-α
locus
Incremented maturated monocytes and pro-inflammatory cytokines expression (57–59)
H4 Hyperacetylation
↑ H3K4me3 Alteration of gene expression and IRF1 overexpression (60,61)
↑ H4 acetylation Altered gene expression; increased IRF1, RFX1, BLIMP1, IL4, INF-γ and INF-α levels (59,62,63)
HAT/HDAC imbalance
Human SLE T cells ↑ H3K27me3 Decreased HPK1, INF-γ and IgG expression; T-cell overactivation and B-cell overstimulation (64)




↑ H3 acetylation Overexpression of CD11a, CD70 and RFX1 autoantibody and autoreactivity overstimulation (20,25,67)
↓ H3K9me3
↓ H3K27me3 CD11a overexpression induction of inflammation (68,69)
↑ H3K18ac Increased IL17A expression and tissular damage; down-regulated IL17F and IL2 expression and DNA
methylation and DNMT3 activity
(70)
↓H3K27me3
↑ H3K18ac Decreased IL-17F expression; induction of tissue damage (23)
↓H3K27me3
↑ H3K27me3 Down-regulation of IL-2 and DNMT3A expression; altered regulatory T lymphocytes; B-cell overactivation (6,51,71,72)
↓ H3K18ac
↓ Recruitment of HDAC1
↑ H3K4me3 and H4ac Up-regulation of IL17A and IL17F levels, CD70, CD40L and TLR2 expression; high immunological reactivity (73)
↓ H3K9me3
↑ HAT p300 Deregulated IL10 and auto-antibodies production; increased tissue damage (74)
↑ H3K18ac
↑ H3ac Low RFX1 expression; augmented IL17, IL6 and pSTAT3 levels (25)
↓ H3K9me3









↓ H3K4me3 Decreased TNFAIP3 mRNA levels; up-regulation of INF-γ and IL17 expression (77)
Human SLE TH17 cells ↑ H3K4me3 Increased IL23 production and pSTAT3 expression (78)
↓ H3K27me3
Human SLE Treg cells ↓ H3K27me2 and H3K4me3 Increased Treg cell differentiation and Foxp3 expression (79)
Human PBMC Hypermethylation Down-regulation of HDAC6 levels; disrupted gene expression (80)
Human SLE Dendritic cells ↓ H3K4me3 and H3K27me3 Increased renal damage and IRF1 production (53)
Human B cells ↑ H3k4me3, H3K9ac and H3K14ac Alteration of chromatin decondensation and gene expression (81)
↓ H3K27me3 and H3K9me3
Human neutrophil extracellular
traps (NET)
↑ H4K8ac, H4K12ac, H4K16ac and
H2BK12ac
High apoptosis activity (82)
↑ H3K27me3
MRL-lpr/lpr splenocytes ↓ H3 and H4 global acetylation Aberrant histone codes and pathogenesis (83)
↑ H3 and H4 global methylation
↓ H3K4me
Mouse CD4þ T cells ↑ H3 acetylation Increased PP2Ac and IL17 levels; predisposing glomerulonephritis (84)
MRL-lpr/lp Splenic T CD4þ cells ↓ Global H3K9 hypomethylation Decreased E2H2, p300, CREBP, HDAC7 mRNA levels (75)
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patients with SLE led to IL17A overexpression through increased
histone H3 acetylation and decreased DNA methylation and tri-
methylated H3 lysine 9 (H3K9me3) (20,25).
Similarly, H3 acetylation and di-methylated H3 lysine 4
(H3K4me2) levels were significantly augmented in patients with
lupus, and both factors were associated with the severity of the
disease. Thus, these results showed that aberrant histone mod-
ifications within the CD70 promoter could participate in the
development of lupus by increasing CD70 expression in CD4þ
T cells (65,66).
Hematopoietic progenitor kinase 1 (HPK1) is a negative regu-
lator of T-cell-mediated immune responses that could play a role
in lupus pathogenesis. Using chromatin immune-precipitation
(ChIP) microarray data, Zhang and colleagues (2011) found sig-
nificantly increased H3K27me3 enrichment at the HPK1 pro-
moter of SLE CD4þ T cells in comparison with controls.
Consistent with these findings, overexpressing HPK1 in SLE
CD4þ T cells induced an important reduction in T-cell reactivity.
These data could demonstrate that HPK1 may serve as a novel
target for effective SLE therapy (64).
ncRNAs in SLE
ncRNAs regulate gene expression or silence at the transcriptional
and post-transcriptional level. miRNAs regulate about 60 % of
mRNA, and they are implicated in several ADs such as SLE or
AR, among others, whereas lncRNAs act on regulated complex
of development and differentiation from different immune cells
through expression of active protein (1). Currently, they are con-
sidered excellent biomarkers and therapeutic targets in
ADs (90,91).
Several preclinical and clinical studies have investigated the
role of miRNAs in lupus pathogenesis; however, thus far there
has not been much study of lncRNAs. Thus, we have revised
the main ncRNA epigenetic modifications described in SLE
(Table 3).
Among the main miRNAs postulated as biotargets and related
with SLE pathogenesis were miR125a, miR142-3p/5p, miR155,
miR21 and miR148, among others. Epigenetic evidence suggests
that miR125a expression is decreased in monocytes and PBMCs
of SLE patients. In activated T cells, miR125a targets Kruppel-like
factor (KLF) 13 and then contributes to regulating the expression
of ‘regulated upon activation, normal T cell expressed and
secreted’ (RANTES), also known as CCL5, a known chemokine
associated to inflammatory response (67). Pan et al. (2015) dem-
onstrated that miR-125a was down-regulated in peripheral CD4þ
T cells of SLE patients, acting as a key regulator that controls T-
cell differentiation suppressing STAT3, IL13 and IFN-γ, several
gene factors in CD4þ T cells from miR125a-deficient mice (92).
In addition, Smith and colleagues described that IL16 was a
direct target for miR125a and observed reduced pulmonary
miR125a and enhanced IL16 expression, suggesting the IL16/
miR125a axis as a novel therapeutic target for management of
acute lung injury in SLE (93).
miR146a and miR155 are two of the ncRNAs most involved in
ADs through NF-κB and IFN-dependent conditions. miR146a is a
negative regulator of innate immunity that targets interferon
regulatory factor (IRF) 5, STAT1, tumour necrosis factor receptor
associated factor (TRAF) 6 and IL1 receptor associated kinase
(IRAK) 1, which are crucial elements of type I IFN signalling cas-
cade and signal transducers in NF-kB, respectively. In PBMC of
SLE patients, miR146a directly repressed the transactivation
downstream of type I IFN. Also, inclusion of miR146a into the
patient’s PBMCs reduced the synchronised activation of the type
I IFN pathway (93). In this context, Dai et al. (2008) observed a
clear connection between miR146a expression and oestrogen
production, related to the higher female prevalence of SLE (90,98).
On the other hand, miR155 regulates B-cell activation and
survival, essential parameters for SLE pathogenesis.
Aboelenein et al. (2017) defined PU.1, a regulator of B cells that
enhances TNF-α production, as a target for miR155 in PBMC and
B cells from paediatric SLE patients (95). Furthermore, in vitro and
in vivo studies carried out by Xin and colleagues revealed
another depleted target gene of miR155, the sphingosine-1-
phosphate receptor (S1PR) 1. They observed that miR155 defi-
ciency diminished SLE autoimmune inflammation by targeting
S1PR1 gene in Faslpr/lpr mice.
Complementarily, the serum levels of IL4 and IL17A, released
by Th2 and Th17 cells, were lower in miR155 (−/−) Fas (lpr/lpr)
than in Fas (lpr/lpr) mice. They concluded that miR155 might be
a new target for therapeutic management in SLE (96). However,
an increment of miR155 expression was confirmed in PBMCs
and CD19þ B cells, suggesting their use as diagnostic biomarkers
for SLE patients (97,114); conversely, Lashine et al. detected lower
levels in younger SLE patients. These contradictions could be
explained by the heterogeneity of the disease and the
differences observed in the pathological stages of this disorder
(115). These authors correlated decreased expression of miR155
with IL2 deficiency associated with PP2Ac overexpression.
Another miRNA implicated in the pathogenesis of SLE relating
to IL2 impaired production is miR31. In fact, miR31 miRNA
has been found to bemarkedly under-expressed in patients with
SLE. It targets Ras homologue gene family member A (RhoA), a
negative regulator of nuclear factor of activated T cells (NFAT)
and cell apoptosis that increases the activity of IL2(102).
Therefore, under-expression of miR31 modulates a low produc-
tion of IL2 through targeting RhoA in SLE T cells. Thus, deregu-
lation of the miR31/RhoA axis represents a novel molecular
mechanism that could counteract the IL2 deficiency in patients
with SLE.
Emerging evidence has revealed an association between
miRNA and DNA methylation. Some miRNAs such as miR21,
miR148a and miR126 are overexpressed in CD4þ T cells from
patients with SLE and contribute to inhibiting the expression
of DNMT1 enzyme and inducing hypomethylation. Among
these, miR126 modulates DNA methylation in CD4þ T cells from
lupus patients and contributes to T- and B-cell autoreactivity in
SLE by directly targeting DNMT1. As a consequence of hypome-
thylation on promoter region, an increase in CD11a and CD70
autoimmune-related protein levels is promoted (12,100).
Besides, Stagakis et al. (2011) analysed miR21 in PBMCs from
lupus patients. Compared with healthy CD4þ T cells, miR21 was
significantly increased and correlated with SLE disease activity,
showing enhanced IL10 production and CD40L expression
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Table 3. Deregulated non-coding RNAs epigenetic modifications in SLE
ncRNAs Cell source Target Action References
↓ miR125a Monocytes KLF13 Down-regulated RANTES, immunomodulation of T cells (67,92,93)
PBMC STAT3, IL13, IFN, IL16 genes
↓ miR146a SLE patients IRAK1, IRF5, STAT1, TRAF6, STAT3, ERK, JNK,
p38 MAPK
Negative regulation of type I IFN pathway (94)
Increased LN and lupus activity
High expression of inflammatory cytokine
↑ miR155 B cells S1PR1, PU.1 Altered secretion of IL4, IL17 and IFN-γ and CD40 expression (95–97)
PBMC
↑ miR21, ↑ miR148a, ↑
miR126
T cells from SLE patients, SLE-
prone mice
DNMT1 Regulated CD11a, CD40L, CD70, LFA1 and DNA hypomethylation (98–100)
PDCD4
↓ miR142-3p/5p T cells SAP, CD84, IL-10 Hyperactivity of B and T cells (101)
Increased IgG production
↓ miR31 T cells RhoA Down-regulation of IL2 production and cell apoptosis (102)
↑ miR29a T cells Sp1 Regulated DNMT1, CD70 and CD11a (103)
↓ miR26a, ↓ miR101 T cells EZH2 Regulated Th2, Th17 and Tfh-related genes (104)
↓ miR1246 B cells EBF1, CD40, CD80, CD86 B-cell activated response (105)
↑ miR30a B cells Lyn B-cell proliferation and overactivation (12)
miR34a B cells Foxp3 Regulated B cell (106)
CD4þ T cell Inhibited Treg cell differentiation
miR150 Mouse B cells c-Myb Lymphocyte proliferation (107)
miR181b B cells AID Decreased CSR (108)
Altered antibody diversity
↓ GAS5 PBMC Apoptotic gene Abolished proliferation of T cells and antibody production (109)
B and T cells from mice
↑ NEAT1 Monocytes Type I IFN, IL6, CXCL10 Activated MAPKs and type I IFN pathways (109,110)
Increased cytokine and chemokine production, DNA hypomethylation
↓ linc0949 PBMC IL6, TNF-α Correlated with inflammation, nephritis, SLE activity and complement
component C3 level
(111)
↓ lnc0597 PBMC IL6, TNF-α Increased cytokine expression (111)
Activation of MAPK signalling pathway
↑ MALAT1 PBMC monocytes SIRT1 Increased IL21 production (109)
↑ lnc-DC Dendritic cells STAT3 Modulated T-cell activation (109)
Th17 differentiation and IL2 production
↑ lnc0640 Plasma Phosphatase 4 Promoted SLE pathogenesis (110)
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through the suppression of programmed cell death protein
(PDCD) 4, a selective protein inhibitor of genes involved in
immune responses (114).
In addition, miR142-3p/5p is involved significantly in patho-
genesis of SLE (12,116). Ding et al. (2012) speculated that in CD4þ T
cells from SLE miR142-3p/5p is disrupted and acts to target sig-
nalling lymphocytic activation molecule-associated protein
(SAP)-, CD84- and IL10- genes. It could be the cause of SAP,
CD84 and IL10 increasing SLE-associated translation and T-cell
and B-cell hyper-response (101). Despite the fact that in lupus
CD4þ T cells miR142-3p/5p intracellular levels are low, both
were up-regulated in plasma and renal biopsies of SLE patients.
This may be explained by exocytosis activity of these cells (117).
Decreased levels of miR1246, which target early B-cell factor
(EBF) 1 mRNA specifically, have been found in B cells from SLE
patients, inducing hyperactivation of B cells through surface co-
stimulatory molecules CD40, CD80 and CD86. Activated B cells
in SLE showed a positive feedback loop, where the lower
expression of miR1246 via AKT-p53 signalling induces an up-
regulation of EBF1 mRNA and B-cell activation (105). On the con-
trary, in CD4þ T cells from SLE, up-regulation of miR1246 could
disrupt this amplifying mechanism. These findings provide a
theoretical framework towards the research of novel biological
targets in SLE treatment.
Several studies using microarray analysis detected other
unusual miRNAs in PBMCs from patients with active lupus.
They exhibited increased expression of certain miRNAs
(miR189, miR61, miR78, miR342, miR299-3p, miR198, miR298,
miR574-5p, miR1308, miR638, miR7) or decreased expression
of others (miR196a, miR17-5p, miR409-3p, miR141, miR383,
miR112, miR184, miR186, miR197), but thus far their role in
the pathogenesis of disease is unknown (98,100).
lncRNAs act more specifically in biological functions than
miRNAs, suggesting a strong implication in innate immunity
and inflammatory response. lncRNAs can be measured in
plasma, keeping unaltered in presence of RNAses; hence, they
could be excellent biomarkers (111). Besides, some lncRNAs
allow for distinguishing patients with LN from SLE patients with-
out kidney affection.
Genetic evidence suggests that gene encoding lncRNA
growth arrest-specific (GAS) 5 is implicated in SLE susceptibility.
GAS5 is required for the inhibition of human T-cell proliferation
by rapamycin (109). Several authors have measured lower levels
of GAS5 in CD4þ T cells from SLE patients than from control sub-
jects. However, the results did not show any remarkable
differences regarding kidney affection between studied patients
(118–120).
Furthermore, abnormal expression of lncRNA nuclear para-
speckle assembly transcript (NEAT) 1 enhances the production
of cytokines and chemokines in SLE patients, especially in
monocytes where it regulates some genes (CXCL9, CXCL10,
CXCL11, CCL8) related to IFN type I pathway. This fact could
indicate that NEAT1 may facilitate the pathogenesis of SLE,
and it may represent a novelty biomarker for diagnosis (109,110).
Interestingly, some active patients of SLE disease present
higher levels of linc0949, which is implicated in SLE disease
activity index 2000 (SLEDAI-2K) score, nephritis and comple-
ment component C level and regulates IL6 and TNF-α
production. linc0949 levels were decreased in PBMCs from
lupus victims, so it could be used in monitoring of disease pro-
gression and treatment efficacy. Similarly, low expression of
lnc0597 has been described in SLE PBMCs. However, it presents
high levels in plasma. lnc0597 could be a regulator of IL6 and
TNF-α cytokine expression, both of them implicated in SLE
pathogenesis (111).
Contrarily, metastasis-associated lung adenocarcinoma tran-
script (MALAT) 1, which regulates the sirtuin (SIRT) 1 signalling
pathway and thus the production of IL21 in monocytes, was sig-
nificantly increased in PBMCs and monocytes of lupus
patients(109). Considering that SLE patients exhibited higher lev-
els of IL21 than healthy controls, we may conclude a critical role
of MALAT1 in the SIRT1/IL21 pathway to lupus onset.
lnc-dendritic cell (lnc-DC) is implicated in the activation of
STAT3 in dendritic cells and, subsequently, regulates T-cell acti-
vation, Th17 differentiation and IL2 production, participating in
the pathogenesis of SLE. Significant differences in LN and SLE
patients without nephritis have been shown. Thus, lnc-DC could
be a useful biomarker to distinguish LN diagnosis in lupus
patients (109).
Epigenetic modifications as potential biomarkers and
therapeutic targets
A comprehensive understanding of epigenetic approaches to
autoimmune/inflammatory disease is necessary to predict indi-
vidual disease outcomes and the introduction of effective, tar-
get-directed and tolerable therapies. Epigenetic events may, at
least partially, explain inter-individual differences. In this line,
epigenetic biomarkers are proving useful to verify molecular
aberrations and environmental factors. Also, novel targets for
individualised therapeutic interventions are making possible
an advance in prevention, diagnosis and treatment.
Nevertheless, epigenetic therapy needs further study.
Nowadays, drugs targeting epigenome alterations are
focused on molecular inhibitors of DNMTs (DNMTi) and
HDACs (HDACi).
In fact, several DNMTi have been developed, mainly as anti-
cancer agents. These epigenetic modulators cause cell cycle and
growth arrest, differentiation and apoptosis. Validation of co-
therapies using these agents with cytotoxic drugs or radio-
therapy could be crucial because the use of DNMTi offers
improved access to cytotoxic agents or radiation for targeting
DNA–protein complex. Therefore, there is a promising interest
in the use of DNMTi as potential chemo- or radiation sensitisers
to increase clinical response (121). Generically, DNMTi may be
classified into two main classes, depending on their mode of
action: nucleoside analogues and non-nucleoside analogues.
Firstly, nucleoside analogues consist of a cytosine ring con-
nected to ribose or deoxyribose, which may integrate into
DNA or RNA through replacement of cytosine units. Once incor-
porated into DNA and bonded to it covalently, they inhibit
DNMTs activity (122). To date, the most well-characterised
nucleoside analogues are 5-azacytidine and 5 0-aza-2 0-deoxycy-
tidine. Both of them were approved by the Food and Drug
Administration (FDA) to treat myelodysplastic disorders (123),
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so most current preclinical and clinical trials evaluating func-
tional effects and therapeutics targets are focused on cancer
(122,124). The treatment of human or mouse CD4þ T cells with
these DNMTis induces or aggravates lupus-like disease, trigger-
ing T-cell autoreactivity and providing evidence of the implica-
tion ofDNAmethylation in autoimmunity (58). Richardson treated
CD4þ T cells from healthy mice with 5-azacytidine, and then
injected 5-azacytidine into identical animals. Mice receiving 5-
azacytidine-treated cells expressed signs, anti-nuclear antibodies
and complex glomerulonephritis closely related to human lupus
(125). Interestingly, several studies have demonstrated that the
treatment of natural T cells with 5-azacytidine induced overex-
pression of different genes susceptible to methylation, as a con-
sequence of DNMT inhibition. The genes identified were: the T–
B cell co-stimulatory molecules CD70 and CD40L, the T-cell
autoreactivity molecule CD11a, and the protein that integrates
lethal pores into cell membrane perforin. All of them are hypo-
methylated and overexpressed in T cells from lupus patients
(58,126–128). Treatment with 5-azacytidine has been used amply
as drug-induced lupus, and it has enabled confirmation of the
pattern of DNA methylation in SLE.
Additionally, other cytidine analogues have been developed
to improve the properties of azanucleoside agents. Zebularine is
a deoxycytidine derivative that lacks an amino group in position
four of the pyrimidine ring (129). Its oral bioavailability and capac-
ity to reactivate a silenced gene by oral administration have been
well established (130).
Another known DNMTi, 5-fluoro-2 0-deoxycytidine, is a fluo-
ropyrimidine nucleoside analogue that may bind covalently to
DNMTs and form a suicide complex (131); and 5,6-dihydro-5-aza-
cytidine (DHAC) may be incorporated into RNA, inhibiting its
synthesis and DNA methylation in human cell lines (124). SGI-
110 (guadecitabine) has been shown to be effective in DNA
methylation inhibition in both in vitro and in vivo studies.
Also, this second-generation drug seems to act as an immune
modulator (132). To improve 5-azacytidine, CP-400 was designed
independently to the nucleoside transport system and showed
more efficacy. Gemcitabine, the most-used treatment in cancer,
is an anti-metabolite that acts with two active metabolites, inhib-
iting ribonucleoside reductase and/or in DNA replication sup-
planting a cytosine unit (122).
Secondly, the non-nucleoside analogue group includes those
compounds that bind to DNMTs covalently, without a previous
interaction within DNA strand (122). Some DNMTis of this group
are procaine, procainamide, hydralazine, MG98 and RG108,
among others. Procaine and procainamide act by inhibiting
DNMTs, but they are also drugs usually employed as local anaes-
thetics and anti-arrhythmics, respectively. Nonetheless, procai-
namide has exhibited a more selective action on DNMT1 than
on DNMT3a and DNMT3b (133). IM25 was derived from procai-
namide, within an improved toxic profile (122).
Hydralazine was primarily used to treat high blood pressure.
It forms strong hydrogen bonds with arginine and glutamic res-
idues of DNMT1 (123). Like azanucleosides, most current studies
about functional effects and therapeutics targets of non-nucleo-
sides are focused on anti-cancer therapy. However, the treat-
ment with procainamide or hydralazine disrupted genome-
wide epigenetics and induced lupus-like disease. These drugs
cause DNA hypomethylation in T cells and, thus, increased
expression of LFA1, a molecule involved in T-cell activation,
inducing autoreactivity. Similar murine studies have further con-
firmed that procainamide and hydralazine may induce overex-
pression of lupus-associated genes (CD70, CD40L, CD11a),
considering them as SLE-induced drugs (58,126–128).
Complementarily, some non-nucleoside analogues exert pre-
cise DNMT inhibition. Nanaomycin A inhibits DNMT3b selec-
tively; MG98, a second-generation short antisense nucleoside,
acts on DNMT1 mRNA and down-regulates DNMT1 expression;
and RG108 inhibits DNMT1 at catalytic domain. These second-
generation drugs present a less cytotoxic profile (122).
Other modifier drugs of DNA methylation target on DNMTs
are methotrexate, an immune-suppressant used in rheumatic
diseases, and cyclophosphamide, an antineoplastic drug (50).
Methotrexate can deplete SAM levels, the substrate of DNMT,
thus inhibiting it indirectly. On the other hand, cyclophospha-
mide induces DNMT1 activity, implementing DNA methylation.
These epigenetic actions may provide a better understanding of
the efficacy of treating SLE patients with methotrexate or cyclo-
phosphamide (50).
The concept of precise modulation of methylated DNA in T-
cell subsets has transformative potential in the treatment of ADs
and beyond, but the global effects of DNMTis in different cell
types render systemic treatment outcomes unpredictable, dis-
turbing unaffected genes and deregulating them (134).
Unfortunately, SLE patients exhibit hypomethylation of genes,
and only a few of them are hypermethylated; thus, the treat-
ment with DNMTis reverting DNA hypomethylation is not an
option.
Contrarily, different studies have reported HDACis improved
autoimmune and inflammatory diseases (135,137). Accordingly,
two HDACis have attracted special attention: trichostatin A
(TSA) and suberoylanilide hydroxamic acid (SAHA or vorino-
stat), improving proteinuria, spleen weight and glomerulo-
nephritis. Nanomolar concentrations of these have shown
specific and reversible inhibition of HDACs. The effectiveness
of TSA and SAHA on SLE disease has been tested in lupusmurine
models or in vitro, but no data are available yet about the resto-
ration of histone acetylation and treatment in lupus patients.
Daily TSA administration inhibited the production of inflamma-
tory mediators in spleen and kidney of NBZ/W mice, leading to
increased functionality of Treg cells associated with HDC inhib-
ition (138). In this line, Garcia et al. (2005) corroborated in MRL-
lpr/lprmice a correction of site-specific hypoacetylated after TSA
treatment (83). Mishra et al. (2003) reported the ability of TSA and
SAHA in MRL-lpr/lpr mice. These inhibitors decreased levels of
autoantibodies and proinflammatory cytokines such as IFN-γ,
IL12, IL6 and IL10 mRNA, improving kidney and spleen affec-
tion. These inhibitors together were associated with HDACi effi-
cacy to restore acetylation on H3 and H4 (139). Besides, these
authors treated T cells from SLE patients with TSA, and significant
down-regulation of CD154 and IL10 and up-regulation of IFN-γ
were observed. Consequently, the capacity of TSA to interfere in
inflammatory response through regulation of the CD40–CD154
axis (related to diverse immune system pathways), IL10 and IFN-
γ expression supports its potential as a therapeutic agent to
SLE (140).
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ACY-738, a specific HDAC6 inhibitor, increased splenic Tregs
and decreased Th17 cells in NZB/W mice, related to decreased
serum anti-dsDNA levels. Moreover, ACY-738 improved the
phenotype of SLE by inhibiting the production of IL6, IL10
and TGF-β, and deposition of C3 and IgG in glomeruli, reducing
LN (140). CKD-506, another inhibitor of HDAC6, enhanced sur-
vival rate and decreased proteinuria, kidney inflammation and
glomerular infiltration of IgG and C3 in NZB/W F1 mice.
Furthermore, CKD-506 reduced levels of inflammatory cytokines
in serum and kidney (142). Recent studies showed that ITF2357
(givinostat), an inhibitor of class I and II HDACs that is used
mainly in juvenile idiopathic arthritis, increased Treg cells and
Foxp3 acetylation and, thus, inhibited autoantibody and pro-
inflammatory cytokine production in NZB/W mice.
Experiments in animals showed SLE reduced serum and urine
biomarkers (143).
Based on these studies, it has been suggested that HDACi
may be a promising new therapy for SLE. Nevertheless, the clini-
cal effects of HDACi in lupus patients have not been demon-
strated yet. Conversely, histone-modifying drugs have been
used for epilepsy (valproic acid) and oncology (vorinostat, romi-
depsin) therapies (6,144). Additionally, the FDA approved vorino-
stat for the treatment of cutaneous T-cell lymphoma in 2006
(145,146), used in monotherapy or in combination with other drugs
(147–149). On the other hand, givinostat improved juvenile idio-
pathic arthritis (150) and reduced muscle fibrosis in Duchenne
muscular dystrophy, showing an excellent safety profile (151).
In short, epigenetic markers and immune-associated activity
may be used as novel therapeutic targets and biomarkers, sup-
plying possible alternatives to clinical treatment in SLE. Future
research and investigations about epigenome in specific cell
types and organs are needed to support themechanism of action
of these DNMTi and HDACi ‘epidrugs’ in the disease and their
future applications in SLE. This aspect should be studied in
depth, evaluating the efficacy of therapy within these agents,
alone or in combination with existing therapies in clinical trials
of patients with lupus disorders, which complement the results
obtained in recently published preclinical studies.
Diet, epigenetic and SLE linkage
The pathogenic process of ADs is considered a complicated and
complex challenging question. Genetic predisposition and envi-
ronmental factors, such as nutrition, infection, pollution or UV
exposure, can cause autoimmunity and are implicated in the
pathogenesis, although how much of each is not well known
yet. Nutrition and dietary habits are one of the most accessible
external factors, with diet being a possible tool to act on the dis-
ease onset. Generally, it has been recognised that feeding habits,
such as calorie restriction or supplementation with macronu-
trients (fibre, unsaturated fatty acids or specific bioactive com-
pounds (152)), may influence development and predisposition
of pathologies, especially ADs (153). A growing number preclini-
cal and clinical studies have evidenced the relation of dietary
components and patternswith the immune response (154). A clear
example of this is the discordance in the incidence of immune-
mediated diseases in Western countries. In fact, the
Mediterranean diet might support an improvement in diseases
related to the immune system, inflammation or oxidative stress,
confirmed in RA, SLE, cardiovascular disease (CVD), cancer and
neurodegenerative disease patients, among others (155–159). This
diet emphasises vegetables, fruits, nuts, fish and olive oil (OO) as
a main fat source.
Focusing on SLE disorders, there has been a growing body of
preclinical and clinical literature describing the control of lupus
disease by dietary interventions (160). A high-quality diet is of
notable importance since these patients used to be affected with
vitamin and mineral deficiencies, anaemia or high CVD suscep-
tibility (10). A balanced diet and its nutrients exhibit antioxidant,
anti-inflammatory and immunomodulatory properties (10).
Accordingly, a nutritional therapy based on carbohydrate and
protein restriction, and vitamin (A, B, C, D and E) and
omega-3 supplementation with adequate fibre and sodium con-
sumption, enables a reduction in the severity, or prevention, of
disease (10,154,158–162). In spite of multiple studies suggesting the
beneficial properties of nutritional therapy (161,162), more clinical
trials are needed and further research is required.
In this respect, a cross-relation between ADs, diet and epige-
netics may exist. Several authors have shown that certain early
diet habits may lead to metabolic and physiology changes
through epigenetic altered pattern, defining susceptibility to
chronic pathologies with the passage of time (153,163,164). Based
on diet restriction and following specific eating habits, such as
Mediterranean diet or consumption of certain nutrients, they
have shown their implication for modulation of DNA methyla-
tion, histone patterns or ncRNA expression (163,165–168). Even fol-
lowing specific pregnancy-feeding guidelines seems to play a
key role in the epigenetic profile of embryo (153).
Diet is an essential player in homeostasis of epigenetic marks,
making it a top influencer for SLE development (127). To date,
there are some studies about nutrients’ effect on HDAC and
HAT activity or miRNA expression, but diet’s influence on
DNA methylation is better established. There are two main
mechanisms that alter DNAmethylation: (i) availability of methyl
donors, and (ii) disruption of DNMT1 activity (163). The most
widely investigated of them is the influence of nutrients on
methyl group supply for one-carbon metabolism.
Partly, this may be due to levels of SAM, a methyl donor, de-
pendent on dietary micronutrients, such as folate, zinc, methio-
nine, choline, and B6 and B12 vitamins, and oxidative stressors
and age, which may decrease DNMT1 activity. In SLE patients,
high oxidative response and sensitivity to diets deficient in
SAM donors has been observed. For this reason, the mainte-
nance of balance between DNMT1 and SAM levels is a key point
to avoid SLE flares and onset (127,169). Accordingly, Strickland and
colleagues observed that dietary micronutrients which are impli-
cated in methylation process may affect genes through epige-
netic mechanisms in correlation with the severity of disease
(170). A transgenic lupus model with inducible ERK pathway sig-
nalling defect was bred onto lupus-resistant (C57BL/6) and
lupus-susceptible (C57BL/6xSJL) mouse strains. These mice
express a dominant-negative MEK uniquely in CD2þ cells when
doxycycline, a DNMT1 level regulator, is administered in their
drinking-water. Both mouse groups that were fed a diet with
low levels of methyl-related nutrients (choline and methionine)
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showed high renal damage and developed haematuria, while
mice fed with a diet supplemented with high levels of methyl
donors reduced the development of kidney disease. Taken
together, the authors concluded that dietary micronutrients
can contribute to lupus susceptibility and severity through
genetic/epigenetic interactions that affect DNA methylation.
Additionally, SLE patients present decreased levels of vita-
mins, methionine and other methyl-donors in comparison with
healthy individuals. Nevertheless, diet supplemented with vita-
mins (A, B6, C, D or E) resulted in improvement of flares and
symptoms of SLE (10). Ray et al. (2018) hypothesised that expres-
sion of genes susceptible to DNAmethylation in T cells from SLE
patients may be more prevalent in low-micronutrient conditions
than in healthy T cells. They cultured CD4þ T cells from lupus
patients PHA-stimulated in culturemediawith normal or low lev-
els of B6 and B12 vitamins, methionine, folate and choline, and
then measured expression of CD70, perforin and KIR (171). It
should be noted that KIR, perforin and CD70 genes are usually
hypermethylated and overexpressed in SLE (58,125–128). The
authors observed that CD4þ T cells from SLE patients cultured
in low levels of supplements exhibited an increase in these
methylation-sensitive genes (171). In conclusion, SLE patients
may pay attention to their nutrition to avoid low levels of methyl
donors and DNMT activity, preventing lupus flares and onsets,
especially older people with more diet deficiencies.
A large number of articles have reported independently that
some bioactive compounds consumed in diet exert beneficial
properties on SLE, and these same micronutrients act via epige-
netic modulation (10,172,173), although most of them have been
established in cancer. Taking these properties into considera-
tion, we could analyse these studies in order to clarify the
cross-relation among the consumption of these nutraceuticals,
the improvement in SLE disease profile and their effects on epi-
genetic machinery (Table 4). Some of these dietary bioactive
compounds could be curcumin, epigallocatechin gallate
(EGCG), resveratrol, genistein, indole-3-carbinol (I3C) or OO.
Curcumin, a polyphenol from the golden spice turmeric,
inhibited cell proliferation and differentiation and ameliorated
the immune response of Th1 through IFN-γ inhibition.
Besides, this polyphenol reduced Th17 cell response, inhibiting
the expression of relevant proinflammatory cytokines, and
modulated Th17/Treg cell balance in CD4þ from SLE patients,
exhibiting therapeutic profile to this AD (174–176). In experimental
animal studies, curcumin-supplemented diet ameliorated renal
damage and controlled autoantibody and cytokine production
on lupus onset 66,176,177). Similar effects were observed in clinical
trials using curcumin-supplemented diet or curcumin-treated T
cells from SLE patients, regulating Th17/Treg balance of CD4þ
T cells (10,177,178). Complementarily, curcumin is known to
decrease HAT activity at H3ac of IL6 promoter, inhibiting the
release of IL6 and TNF-α (180). Balasubramanyam and colleagues
(2004) postulated that curcumin was the first known p300 spe-
cific natural HAT inhibitor in transcription (181). Moreover, daily
intake of curcumin decreasedmiR21 andmiR155 levels and sup-
pressed DNMT1, DNMT3a and DNMT3b expressions (180).
In this line, different in vitro and in vivo studies support the
modulation action of the green-tea polyphenol ECGC on NF-kB,
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nuclear factor erythroid-derived (Nrf) 2 and T-cell activation.
Overall, EGCG controls inflammation and prevents renal func-
tion impairment. In this line, several in vivo studies showed
depletion of progression in lupus-like syndrome, including glo-
merulonephritis and autoantibody production in ECGC-fedmice
(10,182–184). With regard to epigenetics, EGCG decreased HDACs
and HAT class I activity that affected NF-kB, IL6 expression and
inflammatory response (185), but also, EGCG inhibited histone
methyltransferase EZH2, which adds a methyl group to
H3K27. Moreover, this green-tea polyphenol inhibited DNA
methylation through an interaction with DNMT1. It was able
to form four hydrogen bounds on the catalytic centre of
DNMT1, rejecting the entrance of cytosine residue (186). Also,
DNMT3a and DNMT3b were inhibited in an in vivo study with
EGCG-treated mice (187). Complementarily, antioxidant proper-
ties of green tea could be explained by restoring expression
of antioxidant enzymes, as glutathione S-transferase P (GSTP)
1 by inducing demethylation and DNMT inhibition (123).
Resveratrol, a polyphenol present in tomato, peanuts or skin
of red grapes, showed protective effects in lupus disorders, and
supported its ability to regulate inflammatory genes and tran-
scription factors such as STAT3, NF-kB or cyclooxygenase
(COX) 2, implicated in SLE disease (188,189). Consequently, in oxi-
dative stress and inflammatory response, resveratrol treatment
decreased the expression and activity of DNMT3a and SIRT1,
ameliorating harmful conditions (190). In addition, resveratrol
treatment in human THP-1 macrophages restored levels of
pro-inflammatory cytokines through miR-Let7A overexpression
(191), and controlled miR21 levels, down-regulating NF-kB, TNF-
α, IL1β and IL6 (123).
I3C is abundant in cruciferous vegetable such as broccoli,
cabbage or cauliflower. In NZB/w F1 mice fed with a I3C-sup-
plemented diet, proteinuria and renal affections were decreased
and survival of animals was increased (192). These data confirmed
a beneficial effect of dietary I3C in experimental SLE.
Recently, Eghbalpour et al. (2020) investigated the effect of
I3C on transcriptional profiling of macrophage-derived mono-
cytes (MDMs) from SLE patients in four stages of the wound-
healing process. The results showed that treatment with I3C
could modulate STAT1, THBS1 and ATP2A3 gene expression
involved in wound healing in SLE cases and healthy controls
(193). Additionally, I3C counteracted the effects of staphylococcal
enterotoxin B (SEB), a superantigen inductor of inflammation
and immune cell activation, in SEB-stimulated T cells. This indole
re-established pro-inflammatory cytokines levels and cellular
infiltration, inhibited HDAC class I and decreasedmiR31 produc-
tion. Busbee and colleagues suggested that the regulatory epige-
netic action associated with I3C was the reason for its immune-
inflammatory regulation capacity (194,195).
The isoflavone genistein that is present in soybeans is well
known for its antioxidant effects. Genistein improved the
severity of disease and regulated autoantibody production, pro-
teinuria and renal pathology in lupus patients (10). Recently, Li
et al. (2019) reported that genisteinmay recover epigenetic aber-
rations of Klotho (kidney anti-aging and fibrosis-suppressing
protein) in a mouse kidney disease incurred by unilateral ure-
teral occlusion. The authors used genistein-treated human kid-
ney tubular cells (HK2) and C57BL/6 mouse kidney lysates.
Genistein inhibited DNMT1, DNMT3a and DNMT3b and also
decreased histone acetylation, alleviating renal fibrosis by
Klotho restoration (196). Additionally, levels of miR155 were
down-regulated in MDA-MB-435 and Hs578t cancer cells treated
with genistein (197). The potential effectiveness of genistein in the
restoration of epigenome alterations suggests it is an interesting
dietary supplement in prophylaxis and treatment of several ADs
and cancer.
The beneficial properties of OO in SLE have been described
widely, particularly extra virgin olive oil (EVOO). Aparicio-Soto
and colleagues have demonstrated that SLE-induced mice fed
with EVOO-supplemented diet presented lower renal
Fig. 2. Schematic representation linking key epigenetic mechanism and bioactive compounds consumed in diet. Several micronutrients exhibited regulatory properties
on epigenetics through hypomethylation of DNA, DNMT inhibition and/or regulation of HATs, HDACs and miRNAs. EGCG, epigallocatechin gallate; EVOO/OO, extra
virgin olive oil/olive oil; I3C, indole-3-carbinol.
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incidence and inflammatory mediators, such as matrix metallo-
protease (MMP) 3, prostaglandin (PG) E2, pro-inflammatory
cytokines, Nrf-2/haem oxygenase (HO) 1, MAPKs and NF-kB
signalling pathways (198). These authors also reported that poly-
phenolic fraction of EVOO modulated cytokine production,
attenuating T-cell activation using PBMC from lupus patients
(199). In terms of DNA methylation, EVOO induced changes
in the expression of several inflammatory-related genes in
peripheral leucocytes from patients fed a Mediterranean diet
(200). Moreover, OO exerted demethylating activity and inhib-
ited DNMT1 (201).
In summary, dietary interventions could modify the epige-
netic profile, with numerous studies consolidating this affirma-
tion (Fig. 2). Although several publications report correlating
changes in epigenetic-specific alteration in some genes and its
expression in response to dietary bioactive compounds, to date,
few of them have investigated both influence on lupus and the
functional consequences of modifying nutrition habits.
Conclusion
There is growing evidence for the implication of environmental
factors, such as nutrition, lifestyle or UV exposure, that orches-
trate epigenetic changes in predisposed subjects, contributing to
modulation of SLE onset. Generally, global losses of DNA
methylation and H3 and H4 histone deacetylation have been
identified in lupus disorder. Despite the fact that more accurate
and revealing preclinical and clinical works are required for
understanding the pathogenic mechanism contributing to SLE,
epigenome patterns have been proposed as novel approaches
to SLE therapy.
Accordingly, DNA methylation and histone modification
have been postulated as key targets that could be employed
in the development of individual and precise therapies with
lower or no side effects. Particularly, recent studies have sug-
gested the testing of some ‘epidrugs’, whose mechanism of
action is based on DNMT or HDAC inhibition, underscoring
the capacity of these drugs to modulate target gene expression
defined in SLE.
In fact, the measurement of ncRNAs levels in serum or certain
organs has been established as useful diagnosis tools. Indeed,
significant differences in several miRNAs’ levels were observed
between lupus patients and normal controls, or even in lupus
patients with kidney affection compared with those without kid-
ney damage. These revealing facts suggest miRNAs as new strat-
egies for diagnosis and therapeutic targets of lupus.
Improvement of disease associatedwith somemicronutrients
has been widely demonstrated; notwithstanding, little is known
about their relation with epigenetic alteration in SLE. Although
studies are not conclusive and further research is required, it
seems to be clear that diet supplemented with certain bioactive
compounds could be effective in preventing or avoiding aber-
rant modifications in epigenome to improve SLE onset.
Therefore, the combined use of epigenetic bioactive compounds
with therapeutic drugs could be of interest because of the pos-
sible synergistic effects that may be observed in the treatment of
disease.
Mainly dietary bioactive compounds have been studied
within cancer mice models and only a few preclinical trials, so
emergence studies in SLE and immune-inflammatory disorders
are required for a better understanding. Nonetheless, the effects
of the dietary bioactive compound on the epigenome, a so-
called epigenetic diet, could offer an approach in prevention,
therapy and diagnosis of diseases in the future.
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